Clinical practice with anti-dementia drugs: A consensus statement from British Association for Psychopharmacology

Journal of Psychopharmacology

Volumn 20, Issue 6, 2006, Pages 732-755

  Burns, Alistair ^a   O'Brien, John ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; Treatment guidelines

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLOROQUINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLIOQUINOL; CLONAZEPAM; CYANOCOBALAMIN; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FOLIC ACID; GALANTAMINE; GESTAGEN; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LEVODOPA; MEMANTINE; NOOTROPIC AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; RIVASTIGMINE; SELEGILINE; TACRINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANOREXIA; AROMATHERAPY; BRAIN SCINTISCANNING; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFECT; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; EVIDENCE BASED PRACTICE; EYE TOXICITY; FALLING; GENERAL PRACTITIONER; HEALTH ECONOMICS; HORMONE SUBSTITUTION; HUMAN; HYPERSALIVATION; INTERVENTION STUDY; LACRIMATION DISORDER; LONG TERM CARE; MEDICAL EXPERT; MEMORY; MONOTHERAPY; MULTIINFARCT DEMENTIA; NAUSEA; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARASOMNIA; PATIENT COMPLIANCE; PHOTOTHERAPY; PHYSICIAN; POLYPHARMACY; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHIATRIST; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; REVIEW; RHINORRHEA; RISK REDUCTION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; SYNCOPE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; VOMITING; WITHDRAWAL SYNDROME;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COMBINED MODALITY THERAPY; CONSENSUS DEVELOPMENT CONFERENCES; DEMENTIA; DEMENTIA, VASCULAR; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LEWY BODY DISEASE; MEMANTINE; META-ANALYSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 33750329955     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106068299     Document Type: Review

References (165)

1. Aarsland D, Hutchinson M, Larsen J P (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18(10): 937-941
2. Aarsland D, Laake K, Larsen J P, Janvin C (2002) Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72: 708-712
3. Aarsland D, Ballard C, Larsen J P, McKeith I, O'Brien J, Perry R (2005) Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 66(5): 633-637
4. Aisen P S, Schafer K A, Grundman M, Pfeiffer E, Sano M, Davis K L, Farlow M R, Jin S, Thomas R G, Thal L J (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. [see comment] JAMA 289(21): 2819-2826
5. Alzheimer's Disease Society (1995) Managing Dementia in the Community. Alzheimer's Disease Society, London
6. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. American Psychiatric Publishing Inc., Arlington, VA
7. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Publishing Inc., Arlington, VA
8. American Psychiatric Association (2000) DSMIII. American Psychiatric Publishing Inc., Arlington, VA
9. Anderson I M, Nutt D J, Deakin J F W (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 14: 3-20
10. Audit Commission (2002) Forget me Not 2002: developing mental health services for older people in England. London, Audit Commission, p. 48
11. Baldwin D S, Anderson I M, Nutt D J, Bandelow B, Bond A, Davidson J R, den Boer J A, Fineberg N A, Knapp M, Scott J, Wittchen H U (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. British Association for Psychopharmacology 19(6): 567-596
12. Bhanji N H, Gauthier S (2003) Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies. International Psychogeriatrics 15: 179
13. Birks J, Grimley Evans J (2005) Ginkgo Biloba for cognitive impairment and dementia. The Cochrane Database of Systematic Reviews Issue 3. (Search date 2002)
14. Black S, Roman G, Geldmacher D S, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R (2003) Efficacy and tolerability of donepezil in vascular dementia. Stroke 34: 2323-2332
15. Boccardi M, Laakso M P, Bresciani L, Galluzzi S, Geroldi C, Beltramello A, Soininen H, Frisoni G B (2003). The MRI pattern of frontal and temporal lobe atrophy in FTD. Neurobiol Aging 24(1): 95-103
16. Boise L, Camicioli R, Morgan D, Rose J, Congleton L (1999) Diagnosing dementia: perspectives of primary care physicians. Gerontologist 39(4): 457-464
17. Bonelli S B, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M (2004) L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 63: 376-378
18. Bullock R, Connolly C (2002) Switching cholinesterase inhibitor therapy in Alzheimer's disease: donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 17(3): 288-289
19. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res & Opinion 21(8): 1317-1327
20. Burns A, Lawlor B, Dening T (2001) Clinical Guidelines in Old Age Psychiatry. Martin Dunitz, London
21. Burns A, Dening A, Lawlor B (2002) Clinical Guidelines in Old Age Psychiatry. Martin Dunitz, London
22. Burns A, Byrne J, Ballard C, Holmes C (2002) Sensory stimulation in dementia: an effective option for managing behavioural problems. BMJ 325: 1312-1313
23. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H-J, Rogers S L (1999) The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 10: 237-244
24. Cabinet Office Strategy Unit (2002) Risk: improving government's capability to handle risk and uncertainty. Strategy Unit Report, The Stationery Office, London
25. Clare L, Woods R T, Moniz Cook E D, Orrell M, Spector A (2006) Cognitive rehabilitation and cognitive training for Alzheimer's disease and vascular dementia. Cochrane Review
26. Clarke R, Smith A D, Jobst K A, Refsum H, Sutton L, Ueland P M (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol 55: 1449-1455
27. Cody M, Beck C, Shue V M, Pope S (2002) Reported practices of primary care physicians in the diagnosis and management of dementia. Aging Ment Health 6(1): 72-76
28. Collins R, Armitage J, Parish S, Sleight P, Peto R (2002) Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22
29. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105-2115
30. Craig D, Birks J (2005) Rivastigmine for Vascular Cognitive Impairment. The Cochrane Database of Systematic Reviews CD004744
31. Darvesh S, Martin E, Walsh R, Rockwood K (2004) Differential effects of lipid-lowering agents on human cholinesterases. Clinical Biochemistry 37: 42-49
32. De Lepeleire J, Heyrman J (1999) Diagnosis and management of dementia in primary care at an early stage: the need for a new concept and an adapted structure. Theoretical Medicine & Bioethics 20: 215-228
33. Department of Health (2001) National Service Framework for Older People. The Stationery Office, London
34. Department of Health (2005) Improving mental health services by extending the role of nurses in prescribing and supplying medication. Good Practice Guide. HMSO, London
35. Doody R S, Stevens J C, Beck C, Dubinsky R M, Kaye J A, Gwyther L, Mohs R C, Thal L J, Whitehouse P J, DeKosky S T, Cummings J L (2001) Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56(9): 1154-1166
36. Doraiswamy P M, Krishnan K R, Anand R, Sohn H, Danyluk J, Hartman R D, Veach J (2002) Long-term effects of rivastigmine in moderately severe Alzheimer's disease: dose early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 26: 705-712
37. Dougall N J, Bruggink S, Ebmeier K P (2004) Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 12(6): 554-570.
38. Review: Dougall N, Nobili F, Ebmeier K P. Predicting the accuracy of a diagnosis of Alzheimer's disease with 99mTc HMPAO single photon emission computed tomography. Psychiatry Res 131(2): 157-168
39. Downs, M, Cook I, Rae C, Collins K E (2000) Caring for patients with dementia: the GP perspective. Aging and Mental Health 4: 301-304
40. Edwards K, Therriault O'Connor J, Gorman C (2004a) Switching from donepezil or rivastigmine to galantamine in clinical practice (letter to the editor). JAGS 52(11): 1965
41. Edwards K R, Hershey L, Wray L, Bednarczyk E M, Lichter D, Farlow M, Johnson S (2004b) Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord (Suppl 1): 40-48
42. Emre M, Aarsland D, Albanese A, Byrne E J, Deuschl G, De Deyn P P, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa M M, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson's disease NEJM 351: 2509-2518
43. Erkinjuntti T, Roman G, Gauthier S (2004) Treatment of vascular dementia - evidence from trials with cholinesterase inhibitors. Journal of Neurological Sciences 226: 63-66
44. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V (1997) The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 337: 1667-1674
45. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju C V (2002) Efficacy of galantamine in probable vascular dementia and alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359: 1283-1290
46. Ernst E, Pittler M H (1999) Ginkgo biloba for dementia: a systematic review of double blind, placebo-controlled trials. Clin Drug Invest 17(4): 301-308
47. Farlow M, Anand R, Missina J Jr, Hartman R, Veach J (2000) A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 44: 236-241
48. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E (2001) Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57: 613-620
49. Feldman H, Van B B, Kavanagh S M, Torfs K E (2005) Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord 19(1): 29-36
50. Forette F, Seux M L, Staessen J A, Thijs L, Babarskiene M R, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager W H (2003) The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Archives of Internal Medicine 162: 2046-2052
51. Foster S, Tyler V E (1999) Tyler's honest herbal: a sensible guide to the use of herbs and related remedies, 4th edn. New York, The Haworth Herbal Press
52. Fox N C, Black R S, Gilman S, Rossor M N, Griffith S G, Jenkins L, Koller M (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64(9): 1563-1572
53. Gao F Q, Black S E, Liebovitch F S, Callen D J, Rockel C P, Szalai J P (2004) Linear width of the medial temporal lobe can discriminate AD from normal aging: the Sunnybrook Dementia Study. Neurobiol Aging 25: 441-448
54. Geldmacher D S (2003) Long-term cholinesterase inhibitor therapy for Alzheimer's disease: practical considerations for the primary care physician. Prim Care Companion J Clin Psychiatry 5: 251-259
55. Goodwin G (2003) Evidence based guidelines for treating bipolar disorder: recommendations from the British Assocation for Psychopharmacology. Journal of Psychopharmacology 17(2): 149-173
56. Grace J, Daniel S, Stevens T, Shankar K K, Walker Z, Byrne E J, Butler S, Wilkinson D, Woolford J, Waite J, McKeith I G (2001) Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. International Psychogeriatrics 13: 199-205
57. Grundman M, Sencakova D, Jack C R, Petersen R C, Kim H T, Schiltz A, Weiner M F, DeCarli C, DeKosky S T, van Dyck C, Thomas R G, Thal L J (2002) Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci 19: 23-27
58. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22
59. Henderson V W, Paganini-Hill A, Miller B L, Elble R J, Reyes P F, Shoupe D, McCleary C A, Klein R A, Hake A M, Farlow M R (2000) Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 54(2): 295-301
60. Hogervorst E, Yaffe K, Richards M, Huppert F (2005) Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database of Systematic Reviews (3)
61. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis JAMA 288(16): 2015-2022
62. Iliffe S, Manthorpe J (2004) The hazards of early recognition of dementia: a risk assessment. Aging & Mental Health 8(2): 99-105
63. Iliffe S, Wilcock J (2005) The identification of barriers to the recognition of and response to dementia in primary care using a modified focus group method. Dementia; 4: 12-23
64. Iliffe S, Walters K, Rait G (2000) Shortcomings in the diagnosis and management of dementia in primary care: towards an educational strategy. Aging and Mental Health 4(4): 286-291
65. Imbimbo B P (2004) The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opinion on Investigational Drugs 13: 1469-1481
66. Jack C R, Petersen R C, Xu Y C, Waring S C, O'Brien P C, Tangalos E G, Smith G E, Invik R J, Kokmen E (1997) Medial temporal lobe atrophy on MRI in normal aging and very mild AD. Neurology 49(3): 786-794
67. Jagust W (2001) Untangling vascular dementia. Lancet 358: 2097-2098
68. Jick H, Zornberg G L, Jick S S, Seshadri S, Drachman D A (2000) Statins and the risk of dementia. Lancet 356: 1627-1631
69. Jones R (2004) Management of comorbidity in Alzheimer's disease. In (eds), Gauthier S, Scheltens P, Cummings J. Alzheimer's and Related Disorders Annual 2004. Martin Dunitz, London, pp. 145-160
70. Jones R (2005) Supplementary submission to the NICE Health Technology Assessment: Alzheimer's disease - donepezil, rivastigmine, galantamine and memantine (a review). April
71. Jones R W, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R (2004) A multinational, randomised, 12 week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 19(1): 58-67
72. Jorm A F, Korten A E, Henderson A S (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatrica Scandinavica 76: 465-479
73. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H P, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. British Medical Journal 331: 321-327
74. Kaufer D I, Catt K E, Lopez O L, DeKosky S T (1998) Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 51: 1512
75. Kivipelto M, Solomon L, Winblad B (2005) Statin therapy and Alzheimer's Disease. Lancet Neurology 4: 521-522
76. Kivipelto M, Helkala E-L, Hallikainen M, Laakso M P, Hanninen T, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life. BMJ 322: 1447-1451
77. Kivipelto M, Helkala E L, Laakso M P, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomileto J Nissinen A, Soininen H (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Annals of Internal Medicine 137: 149-155
78. Klatte E T, Scharre D W, Nagaraja H N, Davis R A, Beversdorf D Q (2003) Combination therapy of donpezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 17(2): 113-116
79. Launer L J, Ross G W, Petrovitch H, Masaki K, Foley D, White L R, Havlik R J (2000) Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiology of Aging 21: 49-55
80. Le Bars P, Katz M M, Berman N, Itil T M, Freedman A M, Schatzberg A F (1997) A placebo-controlled, double-blind, randomised trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327-1332
81. LeBlanc E S, Janowsky J, Chan B K, Nelson H D (2001) Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285(11): 1489-1499
82. Lehmann M, Gottfries C G, Regland B (1999) Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement. Geriatr Cogn Disord 10: 12-20
83. Lingford-Hughes A, Welch S, Nutt D (2004) Evidence-based guidelines for the pharmacological management of substance misuse, addiction and co-morbidity: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 18(3): 293-335
84. Logan A (2005) When the drugs don't work. Br J General Practice 55: 639
85. Lupton D (1993) Risk as moral danger: the social and political functions of risk discourse in public health. International Journal of Mental Health; 23: 425-434
86. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H (1998) Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 13: 235-239
87. McCaddon A, Hudson P, Davies G, Hughes A, Williams J H, Wilkinson C (2001) Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 12(5): 309-313
88. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. British Medical Journal 305: 673-678
89. McKeith I, Del-Ser T, Spano P F, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, 356: 2031-2036
90. McKeith I G, Galasko D, Kosaka K, Perry E K, Dickson D W, Hansen L A, Salmon D P, Lowe J, Mirra S S, Byrne E J, Lennox G, Quinn N P, Edwardson J A, Ince P G, Bergeron C, Burns A, Miller B L, Lovestone S, Collerton D, Jansen E N, Ballard C, de Vos R A, Wilcock G K, Jellinger K A, Perry R (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124
91. McKeith I, Dickson D, Emre M, O'Brian J T, Feldman H, Cummings J L, Lowe J, Duda J E, Lippa C, Perry E K, Aarsland D, Arai H, Ballard C G, Boeve B Burn D J, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz C G, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria R N, Kaufer D, Kenny R A, Korczyn A, Kosaka K, Lee V M, Lees A, Litvan I, Londos E, Lopez O L, Minoshima S, Mizuno Y, Molina J A, Mukaetova-ladinska E B, Pasquier F, Perry R H, Schulz J B, Trojanowski J Q, Yamada M (2005) Dementia with Lewy bodies: diagnosis and management: third report of the DLB Consortium. Neurology 65(12): 1863-1872
92. McKhann G et al. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force On Alzheimer's disease. Neurology: 34(7): 939-944.
93. McKhann GM et al. (2001). Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol; 58(11): 1803-1809.
94. Maclean L E, Collins C, Byrne E J (2001) Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms and sleep. Int Psychogeriatr 13(3): 277-288
95. Maelicke A (2001) The pharmacological rationale for treating vascular dementia with galantamine (Reminyl). Int J Clin Pract Suppl 120: 24-28
96. Malouf R, Birks J (2005) Donepezil for Vascular Cognitive Impairment. The Cochrane Database of Systematic Reviews, CD004395.pub2
97. Malouf M, Grimley E J, Areosa S A (2003) Folk Acid With or Without Vitamin B12 for Cognition and Dementia. Cochrane Database Systematic Review, (4), CD004514
98. Manthorpe J (2003) Risk and dementia: models for community mental health nursing practice. In Keady J, Clarke C, Adams T (eds) Community Mental Health Nursing, Buckingham, Open University Press
99. Minett T S C, Thomas A, Wilkinson L M, Daniel S L, Sanders J, Richardson J, Littlewood E, Myint P, Newby J, McKeith I G (2003) What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. International Journal of Geriatric Psychiatry 18: 988-993
100. Molloy S, McKeith I, O'Brien J T, Burn D (2005) J Neurol Neurosurg Psychiatry, In press.
101. Montgomery S A, Cowen P J, Deakin W, Freeling P, Hallstrom C, Katona C, King D, Leonard B, Levine S, Phanjoo A, Peet M, Thompson C (1993) Guidelines for treating depressive illness with antidepressants. A statement from the British Association for Psychopharmacology. J Psychopharmacol 7: 19-23
102. Moretti R, Torre P, Antonello R M, Cazzato G (2001) Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. European Journal of Neurology 8: 361
103. Mulnard R A, Cotman C W, Kawas C, van Dyck C H, Sano M, Doody R, Koss E, Pfeiffer E, Jon S, Gamst A, Grundman M, Thomas R, Thal L J (2000) Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 283(8): 1007-1015
104. Murray M D, Lane K A, Gao S, Evans R M, Unverzagt F W, Hall K S, Hendri H (2002) Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Archives of Internal Medicine 162: 2090-2096
105. National Institute for Clinical Excellence (2001) Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Technology Appraisal Guidance no. 19, NICE, London
106. National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 18(suppl. 4): S1-2
107. Neary D, Snowden J S, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert P Y, Albert M, Boone K, Miller B L, Cummings J, Benson D F (1999). Frontotemporal lobar degeneration: A consensus on clinica diagnostic criteria. Neurology 51: 1546-1554
108. Nelson H D, Humphrey L L, Nygren P, Teutsch S M, Allan J D (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288(7): 872-881
109. O'Brien J T, Colloby S, Fenwick J, Williams E D, Firbank M, Burn D, Aarsland D, McKeith I G (2004) Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61(6): 919-925
110. Orgogozo J M, Rigaud A S, Stoffler A, Mobius H J, Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomised placebo-controlled trial. Stroke 33: 1834-1839
111. Page S (in press) Supplementary prescribing and the community mental health nurse. In Keady J, Clarke C, Page S (eds), Community Mental Health Nursing and Dementia, 2nd edn. OUP Press
112. Patterson C, Grek A, Gauthier S, Bergman H, Cohen C, Feightner J W, Feldman H, Hogan D B (2001) The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. The Canadian Journal of Neurological Sciences 28(1): 3-16
113. Page S, Hope K (2005) Post-diagnostic counselling for people with dementia. Dementia Bulletin, Spring
114. Petersen R C, Thomas R G, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jon S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck C H, Thal L J (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine 352(23): 2379-2388
115. Purandare N, Ballard C, Burns A (2005) Preventing dementia. Advances in Psychiatric Treatment 11: 176-187
116. Raskind M, Peskingd E, Wessel T, Yuan W (2000) Galantamine in AD: a 6 month randomised placebo-controlled trial with a 6 moth extension. The Galantamine USA-1 study group Neurology 54: 2261-2268
117. RCPSYCH (2005) Forgetful but not Forgotten. Royal College of Psychiatrists Council Report CR119
118. Rea T D, Breitner J C, Psaty B M, Fitzpatrick A L, Lopez O L, Newman A B, Hazzard W R, Zandi P P, Burke G L, Lyketsos C G, Bernick C, Kuller L H (2005) Stalin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62: 1047-1051
119. Reading P J, Luce A K, McKeith I G (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Movement Disorders 16: 1171-1174
120. Reines S A, Block G A, Morris J C, Liu G, Nessley M L, Lines C R, Norman B A, Baranak C C (2004) Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62(1): 66-71
121. Reisberg B, Doody D, Stoffler A, Schmitt F, Ferris S, Mobius H J (2003) for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341
122. Renshaw J, Scurfield P, Cloke L, Orrell M (2001) General practitioners' views on the early diagnosis of dementia. Br J of Gen Practice 51: 37-38
123. Ridha B H, Josephs K A, Rossor M N (2005) Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 65(3): 481-482
124. Ritchie K, Artero S, Touchon J (2001) Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 56: 37-42
125. Rockwood K, Black S, Robillard A, Lussier I (2004) Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey. Int J Geriatr Psychiatry 19: 954-960
126. Rogers S L, Farlow M R, Doody R S, Mohs R, Friedhoff L T, Donepezil Study Group (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50: 136-145
127. Roman G C, Tatemichi T K, Erkinjuntti T, Cummings J L, Masdeu J C, Garcia J H, Amaducci L, Orgogozo J M, Brun A, Hofman A (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43(2): 250-260
128. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin H B, Hartman R, Gharbawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318: 633-638
129. Sabbagh M, Hake A, Ahmed S, Farlow M (2005) The use of memantine in dementia with Lewy bodies. Journal of Alzheimer's Disease 7(4): 285-289
130. Sadowsky C, Farlow M, Atkinson L, Steadman J, Koumaras B, Chen M, Mirskid (2005) Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Prim Care Companion J Clin Psychiatry 7: 43-48
131. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure F S, Warren K, Jeste D V (2000) Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15: 794-802
132. Sano M, Ernesto C, Thomas R G, Klauber M R, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman C W, Pfeiffer E, Schneider L S, Thal L J (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal of Medicine 336(17): 1216-1222
133. Sastre A, Sherrif F, McShane R (2005) Memantine for Dementia. The Cochrane Database of Systematic Reviews, CD003154.pub3
134. Schilcher H (1988) Ginkgo Biloba: Zeitschrift für Phytotherapie 9: 119-127
135. Sever P S, Dahlof D, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen S E, Kristinsson A, Mclnnes G T, Mehlsen J, Nieminen M, O'Brien E, Osterrgren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandanavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre controlled trial. Lancet 361: 1149-1158
136. Shea C, MacKnight C, Rockwood K (1998) Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. International Psychogeriatrics 10: 229-238
137. Shepherd J, Blauw G J, Murphy M B, Bollen E L, Buckley B M, Cobbe S M, Ford I, Gaw A, Hyland M, Jukema J W, Kamper A M, Macfarlane P W. Meinders A E, Norrie J, Packard C J, Perry I J, Stott D J, Sweeney B J, Twomey C, Westendorp R G (2002) PROSPER study group. PROspective study of pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630
138. Shumaker S A, Legault C, Kuller L, Rapp S R, Thal L, Lane D S, Fillit H, Stefanick M L, Hendrix S L, Lewis C E, Masaki K, Coker L H (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291(24): 2947-2958
139. Silverman D H, Small G W, Chang C Y, Lu C S, Kung D E, Aburto M A, Chen W, Czernin J, Rapoport S I, Pietrini P, Alexander G E, Schapiro M B, Jagust W J, Hoffman J M, Welsh-Bohmer K A, Alavi A, Clark C M, Salmon E, de Leon M J, Mielke R, Cummings J L, Kowell A P, Gambhir S S, Hoh C K, Pelphs M E (2001) Positron emission tomography in evaluation of dementia. JAMA 286(17): 2120-2127
140. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wonnstall H, Harmann T, Schulz J B (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52: 346-350
141. Sparks D L, Scheff S W, Hunsaker J C III, Liu H, Landers T, Gross D R (1994) Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126: 88-94
142. Sparks D L, Sabbagh M N, Connor D J, Lopez J, Launer L J, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62; 753-757
143. Suribhatla S, Dennis M S, Potter J F (2005) A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci 229-230: 147-150
144. Szekely C A, Thorne J E, Zandi P P, Ek M, Messias E, Breitner J C, Goodman S N (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23: 159-169
145. Tariot P N, Solomon P R, Morris J C, Kershaw P, Lilienfeld S, Ding C (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54: 2269-2276
146. Tariot P N, Farlow M, Grossberg G, Graham S M, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Journal of the American Medical Association 291(3): 317-324
147. Taylor A M, Hoehns J D, Anderson D M, Tobert D G (2002) Fatal aspiration pneumonia during transition from donepezil to rivastigmine. Ann Pharmacother 36(10): 1550-1553
148. Thomas A J, Burn D J, Rowan E N, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson J, Sanders J, McKeith I G (2005) A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. International Journal of Geriatric Psychiatry 20(10): 938-944
149. van Hout H, Vernooij-Dassen M, Bakker K, Blom M, Grol R (2000) General practitioners on dementia: tasks, practices and obstacles. Patient Education & Counselling 39: 219-225
150. Walker Z, Grace J, Overshot R, Satarasinghe S, Swann A, Katona C L E, McKeith I G (1999) Int J Geriatr Psychiatry 14: 459-466
151. Wang P N, Liao S Q, Liu R S, Liu C Y, Chao H T, Lu S R (2000) Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 54(11): 2061-2066
152. Whitmer R A, Sidney S, Selby J, Johnston S C, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64: 277-281
153. Wilcock G K, Lilienfeld S, Gaens E (2000a) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multi-centre randomised controlled trial British Medical Journal 321: 1445-1449
154. Wilcock G (2000b) Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. a subgroup analysis of two placebo-controlled trials in vascular dementia. European Neuropsychopharmacology 10:(Suppl. 3): S360
155. Wilcock G, Mobius H K, Stoeffler A (2002) A double-blind placebo-controlled multi-centre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 17: 297-305
156. Wilcock G, Howe I, Coles H, Lilienfeld S, Truven L, Shu Y, Bullock R, Kershaw P (2003) A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20(10): 777-789
157. Winblad B, Poritis N (1999) Memantine in severe dementia. Int J Ger Psych 14: 135-146
158. Wilkinson D, Doody R, Helme R, et al. (2003) Donepezil in Vascular Dementia. Neurology 61: 479-486
159. Wilkinson D G, Howe I (2005) Switiching from donepezil to galantamine: a double-blind study of two wash-out periods. International Journal of Geriatric Psychiatry 20: 489-491
160. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm A L, Zhang R, Haglund A, Subbiah P (2001) A 1-year randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489-495
161. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldwmar G, Wetterholm A L, Haglun A, Zhang R, Schindler R for the Donepezil Nordic Study Group (2006) Dementia and Geriatric Cognitive Disorders 21: 353-363
162. Wolozin B, Kellman W, Ruosseau P, Celesia G G, Siegel G (2000) Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443
163. Woods B, Spector A, Jones C, Orrell M, Davies S (2006) Reminiscence therapy for dementia (Cochrane Review), from The Cochrane Library, Issue 2. John Wiley & Sons, Chichester
164. Woods R, Moniz-Cook E, Iliffe S, Campion P, Vernooij-Dassen M, Zanetti O, Franco M (2003) Dementia: issues in early recognition and intervention in primary care. Journal of the Royal Society of Medicine 96: 320-324
165. Zandi P P, Sparks D L, Khachaturian A S, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer K A, Breitner J C (2005) Cache County Study investigators. Do statins reduce risk of incident dementia and Alzheimer's disease? The Cache County Study. Arch Gen Psych 62: 217-224